Total Payments
$320,032
2024 Payments
$46,816
Companies
37
Transactions
1,387
Medicare Patients
1,962
Medicare Billing
$905,206
Payment Breakdown by Category
Other$259,439 (81.1%)
Food & Beverage$26,406 (8.3%)
Travel$22,546 (7.0%)
Consulting$11,256 (3.5%)
Education$386.01 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $259,439 | 150 | 81.1% |
| Food and Beverage | $26,406 | 1,114 | 8.3% |
| Travel and Lodging | $22,546 | 102 | 7.0% |
| Consulting Fee | $11,256 | 4 | 3.5% |
| Education | $386.01 | 17 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $68,511 | 255 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $62,438 | 184 | $0 (2024) |
| Alkermes, Inc. | $62,286 | 138 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $31,057 | 125 | $0 (2024) |
| ITI, Inc. | $18,637 | 51 | $0 (2023) |
| ABBVIE INC. | $16,932 | 72 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $16,470 | 78 | $0 (2024) |
| Supernus Pharmaceuticals, Inc. | $12,451 | 20 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $11,354 | 126 | $0 (2022) |
| Allergan, Inc. | $9,246 | 49 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,816 | 321 | Otsuka America Pharmaceutical, Inc. ($15,158) |
| 2023 | $70,334 | 287 | Janssen Pharmaceuticals, Inc ($22,147) |
| 2022 | $55,859 | 123 | Alkermes, Inc. ($17,781) |
| 2021 | $40,287 | 82 | Supernus Pharmaceuticals, Inc. ($12,426) |
| 2020 | $21,234 | 106 | Teva Pharmaceuticals USA, Inc. ($6,417) |
| 2019 | $28,638 | 156 | Otsuka America Pharmaceutical, Inc. ($7,971) |
| 2018 | $39,509 | 172 | Neurocrine Biosciences, Inc. ($10,014) |
| 2017 | $17,357 | 140 | Sunovion Pharmaceuticals Inc. ($6,179) |
All Payment Transactions
1,387 individual payment records from CMS Open Payments — Page 1 of 56
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: CNS | ||||||
| 12/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $8.50 | General |
| Category: PSYCHIATRY | ||||||
| 12/19/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $4.28 | General |
| Category: PSYCHIATRY | ||||||
| 12/18/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Neuroscience | ||||||
| 12/17/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/16/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Neurology | ||||||
| 12/13/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,724.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.88 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Central Nervous System | ||||||
| 12/11/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: CNS | ||||||
| 12/11/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Neuroscience | ||||||
| 12/10/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $12.69 | General |
| Category: Neurology | ||||||
| 12/10/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $11.77 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $42.29 | General |
| Category: Neuroscience | ||||||
| 12/07/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $854.10 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $118.62 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: CNS | ||||||
| 12/05/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $29.90 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $1.85 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $27.52 | General |
| Category: Neuroscience | ||||||
| 12/03/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Central Nervous System | ||||||
| 12/02/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: Neurology | ||||||
| 12/02/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $1.42 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 430 | 3,707 | $978,200 | $254,047 |
| 2022 | 2 | 470 | 2,385 | $835,500 | $205,143 |
| 2021 | 2 | 522 | 2,708 | $949,400 | $245,703 |
| 2020 | 2 | 540 | 2,787 | $977,200 | $200,314 |
Total Patients
1,962
Total Services
11,587
Medicare Billing
$905,206
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 396 | 2,113 | $739,550 | $180,579 | 24.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 317 | $110,950 | $42,300 | 38.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 17 | 1,277 | $127,700 | $31,168 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 455 | 2,370 | $829,500 | $203,419 | 24.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $6,000 | $1,725 | 28.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 488 | 2,674 | $935,800 | $241,262 | 25.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 34 | 34 | $13,600 | $4,441 | 32.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 498 | 2,745 | $960,400 | $194,687 | 20.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 42 | 42 | $16,800 | $5,627 | 33.5% |
About Dr. Mohamad Bahnassi, M.D
Dr. Mohamad Bahnassi, M.D is a Addiction Medicine healthcare provider based in Worcester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487754974.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohamad Bahnassi, M.D has received a total of $320,032 in payments from pharmaceutical and medical device companies, with $46,816 received in 2024. These payments were reported across 1,387 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($259,439).
As a Medicare-enrolled provider, Bahnassi has provided services to 1,962 Medicare beneficiaries, totaling 11,587 services with total Medicare billing of $905,206. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Psychiatry
- Location Worcester, MA
- Active Since 09/24/2006
- Last Updated 06/16/2025
- Taxonomy Code 2084A0401X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487754974
Products in Payments
- REXULTI (Drug) $62,553
- LYBALVI (Drug) $53,247
- AUSTEDO (Drug) $52,413
- SPRAVATO (Drug) $30,575
- VRAYLAR (Drug) $26,178
- CAPLYTA (Drug) $18,794
- INGREZZA (Drug) $16,470
- Austedo XR (Drug) $14,437
- LATUDA (Drug) $11,312
- QELBREE (Drug) $9,951
- Dayvigo (Drug) $5,166
- UZEDY (Drug) $971.14
- ARISTADA (Drug) $923.75
- ABILIFY MAINTENA (Drug) $632.34
- SD809-TD (Drug) $595.26
- TRINTELLIX (Drug) $568.75
- Trintellix (Drug) $517.56
- INVEGA SUSTENNA (Drug) $441.41
- Sunosi (Drug) $342.50
- CHANTIX (Drug) $341.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Addiction Medicine Doctors in Worcester
Thomas Kuettel, M.d, M.D
Addiction Medicine — Payments: $47,680
Addiction Medicine $47,680
Wojciech Poluha, Md, MD
Addiction Medicine — Payments: $761.10
Addiction Medicine $761.10
Dr. James Broadhurst, M.d, M.D
Addiction Medicine
Addiction Medicine
Lori Dilorenzo, M.d, M.D
Addiction Medicine
Addiction Medicine
Jeffrey Baxter, Md, MD
Addiction Medicine
Addiction Medicine